🇺🇸 FDA
Pipeline program

Rituximab

RITAZAREM

Phase 3 mab completed

Quick answer

Rituximab for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis is a Phase 3 program (mab) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials